FORMA Therapeutics announces FT4202 granted fast track designation and rare paediatric disease designation to treat sickle cell disease

FORMA Therapeutics announces FT-4202 granted fast track designation and rare paediatric disease designation to treat sickle cell disease

“These designations for FORMA’s lead clinical asset underscore the FDA’s continued recognition of the needs of patients with SCD,” said Frank Lee, chief executive officer of FORMA Therapeutics.

More From BioPortfolio on "FORMA Therapeutics announces FT-4202 granted fast track designation and rare paediatric disease designation to treat sickle cell disease"